Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zeto...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $7 p...
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Kezar Life Sciences (NASDAQ:KZR) with a Buy and lowers the pric...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 ...
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 ...
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of ...
Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (NASDAQ:KZR) announced today that the Center for Drug Evaluation...
